Theravance Biopharma (NASDAQ:TBPH) PT Lowered to $15.00 at HC Wainwright

Theravance Biopharma (NASDAQ:TBPH) had its target price cut by HC Wainwright from $20.00 to $15.00 in a research note released on Tuesday morning, Benzinga reports. They currently have a buy rating on the biopharmaceutical company’s stock.

Several other analysts have also recently issued reports on the company. StockNews.com cut Theravance Biopharma from a buy rating to a hold rating in a research report on Thursday, August 1st. SVB Leerink downgraded Theravance Biopharma from an outperform rating to a market perform rating and reduced their price objective for the stock from $15.00 to $10.00 in a research note on Tuesday. BTIG Research initiated coverage on shares of Theravance Biopharma in a research note on Friday, April 12th. They issued a buy rating and a $21.00 price objective for the company. Finally, TD Cowen lowered their price target on shares of Theravance Biopharma from $10.00 to $9.00 and set a hold rating for the company in a report on Tuesday. Four equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. According to MarketBeat, Theravance Biopharma presently has an average rating of Hold and an average price target of $13.75.

Theravance Biopharma Trading Down 1.9 %

Shares of TBPH opened at $7.68 on Tuesday. The business’s fifty day simple moving average is $9.04 and its two-hundred day simple moving average is $9.08. Theravance Biopharma has a 12 month low of $7.62 and a 12 month high of $11.71.

Theravance Biopharma (NASDAQ:TBPH) last posted its earnings results on Monday, August 5th. The biopharmaceutical company reported ($0.34) EPS for the quarter, missing analysts’ consensus estimates of ($0.09) by ($0.25). Theravance Biopharma had a negative return on equity of 20.63% and a negative net margin of 73.61%. The company had revenue of $14.26 million during the quarter, compared to the consensus estimate of $15.81 million. During the same period last year, the firm posted ($0.28) EPS. Equities analysts expect that Theravance Biopharma will post -0.42 earnings per share for the current year.

Insider Buying and Selling at Theravance Biopharma

In other Theravance Biopharma news, SVP Rhonda Farnum sold 4,000 shares of the business’s stock in a transaction that occurred on Wednesday, July 10th. The stock was sold at an average price of $9.00, for a total value of $36,000.00. Following the completion of the transaction, the senior vice president now directly owns 335,965 shares of the company’s stock, valued at $3,023,685. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 6.90% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in TBPH. Jacobs Levy Equity Management Inc. raised its stake in Theravance Biopharma by 41.6% in the 1st quarter. Jacobs Levy Equity Management Inc. now owns 557,971 shares of the biopharmaceutical company’s stock valued at $5,005,000 after purchasing an additional 163,951 shares during the last quarter. Wellington Management Group LLP raised its holdings in shares of Theravance Biopharma by 68.0% during the 4th quarter. Wellington Management Group LLP now owns 287,102 shares of the biopharmaceutical company’s stock worth $3,227,000 after acquiring an additional 116,164 shares during the period. Oasis Management Co Ltd. increased its holdings in shares of Theravance Biopharma by 5.6% during the 4th quarter. Oasis Management Co Ltd. now owns 1,006,858 shares of the biopharmaceutical company’s stock worth $11,317,000 after buying an additional 53,604 shares during the last quarter. Assenagon Asset Management S.A. purchased a new position in Theravance Biopharma in the first quarter worth approximately $360,000. Finally, Los Angeles Capital Management LLC purchased a new stake in Theravance Biopharma in the 2nd quarter valued at about $286,000. Hedge funds and other institutional investors own 99.10% of the company’s stock.

About Theravance Biopharma

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology.
In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.